Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1440329 | 1.00 | CYP3A4 (0.50) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL5368566 | 1.00 | CYP3A4 (0.50) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL15325590 | 1.00 | CYP3A4 (0.50) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL2818883 | 1.00 | CYP3A4 (0.50) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL19408855 | 1.00 | CYP3A4 (0.50) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL24938939 | 1.00 | CYP3A4 (0.50) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL6951431 | 0.99 | CYP3A4 (0.49) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL9962426 | 0.89 | MAPT (0.51) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL2919878 | 0.88 | CYP3A4 (0.53) | CYP3A4KDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL2919874 | 0.88 | CYP3A4 (0.53) | CYP3A4KDM4EALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110734456-A | compounds, preparation method and medical application thereof | 南京谷睿生物科技有限公司 | 2020-01-31 | — | — | CN | disclosed |
| EP-1903021-B1 | PROCESS FOR PRODUCTION OF FLUOROCOMPOUNDS | TOSOH F TECH INC (JP) | 2015-09-30 | — | — | EP | disclosed |
| CN-101151232-B | Process for production of fluorocompounds | TOSOH F TECH INC | 2011-07-13 | — | — | CN | disclosed |
| US-7615669-B2 | Process for producing fluoro-compounds | TOSOH F-TECH, INC. (JP) | 2009-11-10 | — | — | US | disclosed |
| US-20090030228-A1 | Process for producing fluoro-compounds | TOSOH F-TECH, INC. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1903021-A1 | PROCESS FOR PRODUCTION OF FLUOROCOMPOUNDS | Tosoh F-Tech, Inc. (JP) | 2008-03-26 | — | — | EP | disclosed |
| CN-101151232-A | Process for production of fluorocompounds | TOSOH F TECH INC (JP) | 2008-03-26 | — | — | CN | disclosed |
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2007-05-31 | — | — | US | disclosed |
| US-7166598-B2 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases such as asthma, emesis, an anxiety disorder, pollakiuria, urinary incontinence and irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2007-01-23 | — | — | US | disclosed |
| EP-1140924-B1 | PIPERAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1140924-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035915-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | PKD2, TAC3, PKD1 | CYP3A4 3824/4885KDM4E 1229/4885ALDH1A1 2048/4885 |
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | PKD2, SSTR5, IL5 | CYP3A4 2413/4885KDM4E 3090/4885ALDH1A1 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.